WEDNESDAY, December 30, 2020 (HealthDay News) – Metabolic syndrome (MetSyn) is common in patients with psoriasis and is associated with an increased cardiovascular risk. This is according to a study published online December 28 in the Journal of the American Academy of Dermatology.
Meron Teklu of the National Institutes of Health in Bethesda, Maryland and colleagues studied the effects of MetSyn and its components on early coronary artery disease, which was rated as uncalcified coronary stress (NCB) in psoriasis. Data were included for 260 patients with psoriasis and coronary computed tomography-angiography results.
Thirty-one percent of the participants had MetSyn. The researchers found that exposure to cardiometabolic disease, systemic inflammation, NZB, and high-risk plaque was higher in the MetSyn group. MetSyn and its individual components with increased waist circumference, triglycerides, blood pressure and fasting glucose were associated with the NZB after adjusting the Framingham risk score, lipid-lowering therapy and biological use. Blood pressure and waist circumference remained significantly associated with the NZB after adjusting all other MetSyn factors.
“The metabolic syndrome that is so common in our psoriasis patients drives coronary artery disease in this population by increasing plaque build-up that clogs the arteries of the heart,” a co-author said in a statement. “Our study shows that of the MetSyn components, high blood pressure and obesity are the major contributors to coronary plaque formation and can therefore be good targets for intervention.”
Several authors have disclosed financial ties to the pharmaceutical industry.
Summary / full text (subscription or payment required)